Search results
Showing 1456 to 1470 of 2106 results for technology appraisal
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.
Discontinued Reference number: GID-TAG427
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]
Discontinued Reference number: GID-TAG398
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
Discontinued Reference number: GID-TA10923
Atezolizumab for untreated advanced renal cell carcinoma [ID1365]
Discontinued Reference number: GID-TA10338
Discontinued Reference number: GID-TA10452
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Discontinued Reference number: GID-TA10698
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Discontinued Reference number: GID-TA10822
Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)
Evidence-based recommendations on delgocitinib (Anzupgo) for treating moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable.
Discontinued Reference number: GID-TAG244
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
Discontinued Reference number: GID-TA10242
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Discontinued Reference number: GID-TA10429